All In Biotech

NDA 017771 · Shine

Technelite

Technetium Tc-99m Sodium Pertechnetate Generator · Intravenous · Radioactive Diagnostic Agent

Last checked: Nov 19, 2026Latest source record: Jan 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Nov 16, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

2 Phase 3, 0 recruiting

FAERS reports

16

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 2, 2026.

INDICATIONS AND USAGE: The Technelite generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. Sodium Pertechnetate Tc 99m Injection is used IN ADULTS as an agent for: Thyroid Imaging Salivary Gland Imaging Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux. Nasolacrimal Drainage System Imaging Sodium Pertechnetate Tc 99m Injection is used IN CHILDREN as an agent for: Thyroid Imaging Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 16, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • TECHNELITE · TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR 0.0083-2.7 CI/GENERATOR · SOLUTION, INTRAVENOUS · Discontinued
  • TECHNELITE · TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR 1-20 CI/GENERATOR · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Pertechnetate Generator" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective8
  • dyspnoea2
  • hypersensitivity2
  • nausea2
  • pruritus2
  • vomiting2
  • abdominal discomfort1
  • accidental exposure to product1
  • erythema1
  • hot flush1
  • hypotension1
  • incorrect route of product administration1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20154
20161
20182
20191
20221
20233
20241
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Shine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.